BC Extra | Jul 21, 2017
Company News

Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO while the company seeks Lowe's successor. Neurology and cardiovascular company...
BC Week In Review | Mar 31, 2017
Company News

Cerulean, Novartis deal

Cerulean and Daré will merge in a stock deal; the resulting company will retain Daré's name. Daré’s current CEO, Sabrina Martucci Johnson, will become CEO of the combined company. Daré’s shareholders will own 51-70% of...
BC Week In Review | Oct 24, 2016
Company News

Cerulean, Novartis deal

Cerulean partnered with Novartis to develop nanoparticle-drug conjugates (NDCs) using Cerulean’s Dynamic Tumor Targeting platform with undisclosed Novartis compounds against up to five targets. The platform is designed to create molecules that attack tumor cells...
BC Week In Review | Oct 24, 2016
Financial News

Cerulean completes private placement

Cerulean Pharma Inc. (NASDAQ:CERU), Waltham, Mass.  Business: Drug delivery, Cancer  Date completed: 2016-10-19  Type: Private placement  Raised: $1 million  Shares: 800,000  Price: $1.25  Shares after offering: 28.2 million  Investor: Aspire Capital Fund  Note: The shares...
BC Extra | Oct 19, 2016
Company News

Cerulean, Novartis to develop drug conjugates

Cerulean Pharma Inc. (NASDAQ:CERU) gained $0.27 (40%) to $0.95 after announcing a deal with Novartis AG (NYSE:NVS; SIX:NOVN) to develop nanoparticle-drug conjugates (NDCs). The partners will pair Cerulean's Dynamic Tumor Targeting platform with Novartis compounds...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Sep 5, 2016
Clinical News

CRLX101: Phase II data

Top-line data from an open-label, U.S. and South Korean Phase II trial in 115 patients with metastatic RCC who progressed after 2-3 prior lines of therapy showed that 15 mg/m 2 IV CRLX101 on days...
BC Week In Review | Sep 5, 2016
Company News

Cerulean cancer news

Cerulean will reduce headcount by 21 (48%) to 23 after lead candidate CRLX101 missed the primary endpoint in a Phase II trial to treat metastatic renal cell carcinoma (RCC) in combination with Avastin bevacizumab. CRLX101...
BC Week In Review | May 16, 2016
Clinical News

CRLX101: Phase II data

Cerulean reported data from 18 patients with platinum-resistant ovarian cancer in the first stage of an open-label, U.S. Phase II trial showing that 15 mg/m 2 IV CRLX101 plus 10 mg/kg Avastin bevacizumab every 14...
BC Week In Review | May 16, 2016
Clinical News

CRLX101: Phase I/II started

Cerulean said NIH’s NCI began an open-label, U.S. Phase I/II trial to evaluate IV CRLX101 in combination with oral Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). The Phase I portion will enroll up...
Items per page:
1 - 10 of 87
BC Extra | Jul 21, 2017
Company News

Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO while the company seeks Lowe's successor. Neurology and cardiovascular company...
BC Week In Review | Mar 31, 2017
Company News

Cerulean, Novartis deal

Cerulean and Daré will merge in a stock deal; the resulting company will retain Daré's name. Daré’s current CEO, Sabrina Martucci Johnson, will become CEO of the combined company. Daré’s shareholders will own 51-70% of...
BC Week In Review | Oct 24, 2016
Company News

Cerulean, Novartis deal

Cerulean partnered with Novartis to develop nanoparticle-drug conjugates (NDCs) using Cerulean’s Dynamic Tumor Targeting platform with undisclosed Novartis compounds against up to five targets. The platform is designed to create molecules that attack tumor cells...
BC Week In Review | Oct 24, 2016
Financial News

Cerulean completes private placement

Cerulean Pharma Inc. (NASDAQ:CERU), Waltham, Mass.  Business: Drug delivery, Cancer  Date completed: 2016-10-19  Type: Private placement  Raised: $1 million  Shares: 800,000  Price: $1.25  Shares after offering: 28.2 million  Investor: Aspire Capital Fund  Note: The shares...
BC Extra | Oct 19, 2016
Company News

Cerulean, Novartis to develop drug conjugates

Cerulean Pharma Inc. (NASDAQ:CERU) gained $0.27 (40%) to $0.95 after announcing a deal with Novartis AG (NYSE:NVS; SIX:NOVN) to develop nanoparticle-drug conjugates (NDCs). The partners will pair Cerulean's Dynamic Tumor Targeting platform with Novartis compounds...
BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Sep 5, 2016
Clinical News

CRLX101: Phase II data

Top-line data from an open-label, U.S. and South Korean Phase II trial in 115 patients with metastatic RCC who progressed after 2-3 prior lines of therapy showed that 15 mg/m 2 IV CRLX101 on days...
BC Week In Review | Sep 5, 2016
Company News

Cerulean cancer news

Cerulean will reduce headcount by 21 (48%) to 23 after lead candidate CRLX101 missed the primary endpoint in a Phase II trial to treat metastatic renal cell carcinoma (RCC) in combination with Avastin bevacizumab. CRLX101...
BC Week In Review | May 16, 2016
Clinical News

CRLX101: Phase II data

Cerulean reported data from 18 patients with platinum-resistant ovarian cancer in the first stage of an open-label, U.S. Phase II trial showing that 15 mg/m 2 IV CRLX101 plus 10 mg/kg Avastin bevacizumab every 14...
BC Week In Review | May 16, 2016
Clinical News

CRLX101: Phase I/II started

Cerulean said NIH’s NCI began an open-label, U.S. Phase I/II trial to evaluate IV CRLX101 in combination with oral Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). The Phase I portion will enroll up...
Items per page:
1 - 10 of 87